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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
A critical analysis of articles from the MEDLINE data-
base was carried out using the following keywords (MeSH 
terms): asthma, asthma/epidemiology, asthma/therapy, 
oxygen therapy, prednisone, prednisolone, dexametha-
sone, mineralocorticoids, glucocorticoids, adrenal cortex 
hormones, bronchodilators, albuterol, terbutaline, fenoter-
ol, salmeterol, formoterol, budesonide, fluticasone, bam-
buterol, leukotriene receptor antagonists, montelukast, 
omalizumab, aminophylline, administration and dosage, 
administration, oral, administration, inhalation, inhalation 
devices, intramuscular injection, intravenous injection, 
subcutaneous injection, treatment outcome, side effects, 
risk factors, mortality, hospitalization.
DEGREE OF RECOMMENDATION AND STRENGTH OF EVIDENCE
A: Experimental or observational studies of higher 
consistency.
B: Experimental or observational studies of lower 
consistency.
C: Case Reports (non-controlled studies).
D: Opinion without critical evaluation, based on con-
sensuses, physiological studies or animal models.
OBJECTIVES
To make practical recommendations for the treatment of 
asthma in childhood, based on a critical analysis of evi-
dence published in the medical and scientific literature. 
Asthma in childhood: drug therapy
INTRODUCTION
Asthma is the most prevalent chronic disease in child-
hood. In Brazil, the prevalence of active asthma in school-
children and adolescents is estimated at 19% and 24%, re-
spectively, with regional variations (B)1.
The use of more specific medications with fewer side 
effects has made the treatment for asthma safer and more 
effective. The approach of the asthma attack must be start-
ed by evaluating how severe the crisis is, which determines 
the treatment to be immediately instituted. The prophy-
lactic treatment allows the disease control by decreasing 
the frequency and severity of the attacks and improves the 
child’s quality of life (A)2,3.
DRUG TREATMENT OF THE ASTHMA ATTACK 
1. CAN THE EVALUATION OF ASTHMA ATTACK SEVERITY BE 
MADE BASED ON CLINICAL PARAMETERS?
The use of clinical scores, associated with oximetry mea-
surements and peak expiratory flow contributes to assess 
the severity of the attack. Measurements, carried out after 
the initial use of inhaled β-adrenergic agents, are better pre-
dictors of asthma attack severity than the same measure-
ments pre-treatment. Pre-treatment oximetry (≤ 93%) is a 
parameter with high specificity; however it has low sensi-
tivity for attack severity (respectively, 92% and 35%). When 
determining the attack severity, the main clinical parameters 
is the assessment of the mental state, dyspnea, capacity to 
complete sentences, use of accessory musculature, presence 
of wheezing, respiratory and heart rates. The clinical score 
that is usually employed is the modified Wood-Downes 
score (A)3-5.  The peak flow (PF) measurements can be ob-
tained in children as early as from kindergarten and show a 
direct association with the forced expiratory volume in one 
second, or FEV1. In patients older than 12, the PF, at the 
emergency service, constitutes a good tool to evaluate 
the severity and evolution of the asthma attack. 
Moreover, in young children (> 6 years) comparing PF 
and FEV1 shows good association – positive and signifi-
cant Pearson’s coefficient (r = 0.23, p = 0.0008).
PF values  equal to or above 40% after 15 minutes of 
treatment suggest a favorable outcome with a sensitivity 
of 74%, specificity of 100% and positive predictive value of 
100%. Values  < 30% are predictive of an adverse outcome 
with a sensitivity of 54%, specificity of 93% and positive 
predictive value of 87% (A)6,7.
RECOMMENDATION
Clinical evaluation (clinical scores) is recommended, asso-
ciated with oximetry measurements and peak expiratory 
flow to determine the severity of the attack (A)3-7.
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2. MUST THE TREATMENT OF SEVERE ATTACK ALWAYS BE 
CARRIED OUT AT THE HOSPITAL? 
The patient with a severe attack should be hospitalized. 
Although rare, mortality from asthma is a possibility that 
should be considered in severe patients (A)8,9. Early oxy-
gen administration can prevent severe hypoxia that is as-
sociated with mortality. Oxygen therapy is indicated for 
signs of respiratory failure and when the oximetry is below 
93% (A)4.
RECOMMENDATION
Considering the efficacy of hospital therapy and the possi-
bility of a fatal outcome, it is recommended that the patient 
with a severe asthma attack always be hospitalized (A)4,8,9.
3. IS THE INHALED ROUTE MORE EFFECTIVE THAN THE ORAL 
ONE FOR BRONCHODILATOR (BDL) USE DURING THE ATTACK? 
The preferred route for bronchodilator use is the inhaled 
one. Comparison with the oral administration showed 
that the action of inhaled BDL is faster and has fewer side 
effects (A)10.
In the treatment of moderate to severe attacks in emer-
gency services, high and repeated doses of β2-agonists are 
the initial therapy of choice. The β2-agonist can be admin-
istered at intervals of 10 to 30 minutes or up to four inha-
lations at a time. BDL therapy under continuous nebuli-
zation is also effective for the treatment of acute asthma 
attack; however, there is little evidence in the pediatric age 
group. In adults, hospitalization rates were reduced in pa-
tients treated with continuous nebulization in relation to 
intermittent inhalation (RR: 0.68, 95% CI: 0.5 to 0.9) with 
the best responses being observed in patients with severe 
lower airway obstruction (RR: 0.64, 95%  CI: 0.5 to 0.9). 
There were no significant differences regarding side effects 
between the two forms of bronchodilator administration 
when the mean differences were evaluated with respect to 
the basal heart rate (-2.87, 95% CI: -6.0 to 0.3) and blood 
pressure parameters (-1.75, 95% CI: -5.6 to 2.1) (A)11.
RECOMMENDATION
The inhaled route is preferred for β2-agonist use during the 
asthma attack (A)10,11.
4. IN CHILDREN, IS THE USE OF BRONCHODILATORS 
THROUGH DOSE-METERED INHALER AS EFFECTIVE AS THE 
JET NEBULIZER? EVEN IN SEVERE ATTACKS? 
In children with mild to moderate asthma, the use of 
a dose-metered inhaler to administer bronchodilators 
results in similar effects to that of using a jet nebuliz-
er (B)1 (A)2,3. The dose-metered inhaler requires less time 
for using it and the side effects are also less frequent (with 
aerosol use). A systematic review of studies that compared 
the use of bronchodilators with spacers or nebulizers in 
children showed that the relative risk for hospitalization 
in children using spacers, compared with those who used 
nebulizers was 0.72 (95%  CI: 0.47 to 1.09). The emer-
gency service stay duration was shorter with the spray 
attached to spacers, with a difference of less 0.53 hours 
(95%  CI: -0.62 to -0.44 hours). The mean heart rate was 
lower with the use of spacers, with a difference of less 6.27% 
of the basal frequency (95% CI: -8.29 to -4.25% basal) (A)12.
In children younger than five years, the use of dose-
metered inhalers shows better results than the use of 
β2-adrenergic agent in the jet nebulizer. The use of dose-
metered inhalers decreased the rate of hospitalization (OR: 
0.42, 95% CI: 0.24 to 0.72, p = 0.002), and this decrease was 
more significant among children with moderate to severe 
attacks (OR, 0.27, 95%  CI, 0.13 to 0.54, p  =  0.0003). The 
clinical evaluation was also greater with the use of dose-me-
tered inhalers, assessed by the clinical score improvement 
(mean difference of 0.44, 95% CI: 0.68 to 0.20, p = 0.0003). 
However, it is important to consider that for some chil-
dren, especially those younger than three years, anxious or 
in overall poor health, there is a difficulty in the effective 
administration of the medication. Lack of coordination be-
tween inspiration and device use is one of the reasons for 
the use of spacers with mouthpieces or face masks (A)12,13.
RECOMMENDATIONS
Administration of bronchodilators to treat asthma attacks 
in children can be accomplished by means of dose-me-
tered inhalers or jet nebulizer. The metered-dose inhaler 
spacers should be coupled with a face mask or mouthpiece. 
In severe asthma attacks, when the child shows decreased 
cooperation or capacity to use the medication, jet nebu-
lizer is recommended (A)12,13.   
5. IS THE EFFICACY AND SAFETY OF SHORT-ACTING BRON-
CHODILATORS (SALBUTAMOL X FENOTEROL X TERBUTALINE) 
SIMILAR AMONG THEM?
Salbutamol, fenoterol and terbutaline are short-acting 
bronchodilators commonly used in asthma attacks. Com-
parison of efficacy in the treatment of asthma shows simi-
lar bronchodilator effect, with an action onset in about 5 
minutes and similar intensity and duration for the three 
drugs (B)14. There is evidence of greater toxicity of fenoter-
ol, which can be attributed to the higher doses sold in the 
formulas or the higher affinity with β1 and α receptors. 
Comparison of side effects showed that the mean increase 
in heart rate was 29 bpm, 8 bpm and 8 bpm, respectively 
for fenoterol , salbutamol and terbutaline. Similarly, de-
crease in serum potassium was 0.76 mmol/L, 0.46 mmol/L 
and 0.52 mmol/L (A)15.
RECOMMENDATION 
The three bronchodilators have similar clinical efficacy. 
There is evidence suggesting higher toxicity with the use 
of fenoterol (A)15.
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6. IN A SEVERE ATTACK, IS THE EFFICACY OF THE SUBCU-
TANEOUS AND INTRAVENOUS ROUTES HIGHER THAN THAT 
OF THE INHALED ONE FOR E2-ADRENERGIC AGENT ADMIN-
ISTRATION?
Inhaled route is preferred for the administration of 
β-adrenergic agents. Use of epinephrine and terbutaline 
subcutaneously is also effective, with the action onset 
in about 5 minutes and lasting for about 4 hours. Some 
clinical trials in children showed similar efficacy between 
the two routes, but the subcutaneous route may have 
more side effects. It may be an option in patients unable 
to use the inhaled route in emergency services (B)16,17.
Few clinical trials have evaluated the use of intra-
venous β-adrenergic agents for the treatment of severe 
asthma. In adults, the comparison of intravenous and 
inhaled salbutamol shows greater efficacy and fewer side 
effects with the inhaled route (B)18.
RECOMMENDATION
Inhaled route is preferably recommended for the use of 
β-adrenergic agents in asthma attacks. Subcutaneous 
and intravenous routes are associated with a greater in-
cidence of side effects (B)16-18.
7. IS THE USE OF INHALED IPRATROPIUM BROMIDE (IB), 
ASSOCIATED WITH E2-AGONIST, MORE EFFECTIVE THAN E2-AGONIST ALONE IN THE TREATMENT OF ACUTE ASTHMA 
ATTACK IN CHILDREN? 
Several studies have evaluated the use of IB associated 
with β2-agonists in non-hospitalized patients in an at-
tempt to reduce the duration of emergency service stay 
and prevent hospitalizations. In children treated in emer-
gency services and who received inhaled albuterol and 
systemic corticosteroids, the addition of ipratropium to 
three inhalations of β2-agonist carried out for 1 hour was 
not associated with a significant reduction in hospital-
ization rates (18% vs. 22% in the control group) (A)3,19.
However, in children and adolescents treated in 
emergency services with severe attacks, IB can show 
some benefit. In these patients, adding IB repeated 
doses (2 doses of 500  μg at 20-minute intervals for a 
period of one hour) decreased the rate of hospitaliza-
tion by 15.1%, in relation to the control group treated 
with β2-agonist and corticosteroids. It is estimated that 
it would be necessary to treat 6.6 patients to prevent 
one hospitalization. Hospitalization rates did not differ 
between the two groups for patients with moderate at-
tacks (A)4,20. 
In association with β2-agonists, the use of high and 
repeated doses of IB (250 to 500  μg/dose at 20-to-40- 
minute intervals for an hour) was more effective than 
the use of a single IB dose in improving lung function. 
Adding a single IB dose to β2-agonist did not reduce 
hospitalization rates, either (B)1 (A)2,21,22.
The use of this drug combination (repeated nebulized 
IB doses added to treatment with systemic corticosteroids 
and frequent administration of β2-agonists) in hospitalized 
patients did not show any benefit with regard to time of 
hospitalization, clinical evolution or need for additional 
treatment (A)6,23.
The association of IB to inhaled β2-adrenergic agents in 
childhood has shown to be safe. Adding IB to β2-agonists 
at high and repeated IB doses (250 or 500  μg per dose, 
every 20 minutes, two or three times), does not increase 
side effect symptoms, such as tremors, nausea and vomit-
ing (B)1 (A)22. 
RECOMMENDATIONS
In patients with mild to moderate asthma attacks, there are 
no benefits in the association of IB to β2-agonist. Thus, this 
association is not routinely recommended for children and 
adolescents with asthma attacks (A)3,4,19,20.
The early addition of multiple IB doses can be benefi-
cial in reducing hospitalization rates of children with se-
vere asthma attacks (A)20.
8. ARE INHALED CORTICOSTEROIDS EFFECTIVE FOR THE 
ASTHMA ATTACK TREATMENT?
Inhaled corticosteroids are not recommended for rescue 
treatment in asthma. There are few studies assessing the 
effect of rescue inhaled corticosteroids. According to the 
comparison of continuous beclomethasone or during cri-
ses (for two weeks), the continuous use was associated with 
fewer exacerbations (mean 0.97) than the intermittent use 
(mean 1.69)  (A)24. A study in hospitalized adult patients 
showed similar efficacy between the use of inhaled corti-
costeroids at high doses or systemic use, but all patients 
initially received intravenous corticosteroids for 48 hours, 
in addition to inhaled β-adrenergic agent (A)25.
RECOMMENDATION
Use of inhaled corticosteroids is not recommended for 
asthma rescue treatment in children (A)24. 
9. IS THE ORAL ROUTE AS EFFECTIVE AS THE INTRAVENOUS 
ONE FOR CORTICOSTEROID USE DURING THE ASTHMA AT-
TACK? WHAT ABOUT THE INTRAMUSCULAR ROUTE?
The use of oral corticosteroids is as effective as the in-
travenous or intramuscular routes in acute asthma. Par-
enteral route is indicated only in severe cases where the 
drug oral administration is contraindicated. Comparison 
of two groups of children treated at the emergency room 
for moderate to severe asthma attacks and randomized to 
receive methylprednisolone (2 mg/kg) by oral or intrave-
nous route, showed that after 4 hours of treatment, there 
was no difference in clinical and functional evolution (re-
spiratory rate, pulse oximetry, clinical score and FEV1). 
Forty-eight percent and 50% of the patients required hos-
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pitalization, respectively, in oral and intravenous groups 
(non-significant risk increase = 2%, 95% CI = 21% -25%, 
p = 0.08) (A)26.
Use of intramuscular corticosteroids (0.6  mg/kg in a 
single dose of dexamethasone) in children treated with 
acute asthma was also as effective as the use of oral cor-
ticosteroid (2 mg/kg/day of prednisone for five days). The 
clinical score variation after four days of treatment was 
similar in both groups (difference 0.2, 95% CI 0.4 to 0.7). 
The proportion of patients discharged and that required 
readmission in a follow-up period of two weeks was also 
similar in both groups (absolute risk increase of 1.8%, 
95% CI: -5.4 to 9%) (A)27.
RECOMMENDATION
During an acute asthma attack, the use of oral corticoste-
roids is as effective as the intravenous or intramuscular 
routes of administration (A)26,27. 
10. DOES THE RECURRENT USE OF ORAL CORTICOSTEROIDS 
FOR SHORT PERIODS BRING SIDE EFFECTS? 
Use of oral corticosteroids for a short period of time, in-
termittently, over several years can result in a reduction in 
bone mass gain, and cause an increased risk of osteopenia 
in children with asthma  (B)28. There are also changes in 
bone metabolism in adults who use this therapy (B)29.
Although the side effects caused by the use of systemic 
corticosteroids are dose-dependent according to the evi-
dence, they are also dose-cumulative (B)28. Thus, evidence 
shows that the administration of higher doses of oral cor-
ticosteroids for a short period of time should be recom-
mended, instead of continuous use, in order to reduce the 
risk of adverse systemic effects (B)30.
RECOMMENDATION
Use of oral corticosteroids for short periods of time is 
recommended to minimize side effects, which are dose-
dependent and dose-cumulative (B)28,30.   
11. IS AMINOPHYLLINE EFFECTIVE IN THE TREATMENT OF 
SEVERE ASTHMA ATTACKS? AS INITIAL DRUG TREATMENT? 
AS ADJUNCT TREATMENT? IS IT SAFE?
The use of aminophylline became unnecessary in routine 
treatment of acute asthma, compared to the efficacy and 
safety of short-acting β2-adrenergic aerosol, supplemented 
with oral steroids. Aminophylline confers no additional 
clinical benefits and may cause side effects by the small 
margin of therapeutic safety. A systematic literature review 
selected seven clinical trials and included 380 children 
with acute severe asthma requiring hospital admission. Six 
of these studies evaluated patients who failed to respond to 
the therapeutic use of β2-adrenergic agents and corticoste-
roids. Addition of intravenous aminophylline to this treat-
ment improved lung function in 6 hours, but there was no 
significant clinical improvement. There was no reduction 
in the duration of hospitalization and the need for inhaled 
medication. There is no conclusive evidence on the impact 
of aminophylline use on intensive care admission rates, the 
need for mechanical ventilation and oxygen therapy. There 
was a higher incidence of vomiting in the groups receiving 
aminophylline (A)31.
A recent clinical trial showed a reduction in the du-
ration of hospitalization in children who received amino-
phylline as compared to intravenous salbutamol in severe 
asthma attacks. Two groups of children aged 1 to 16 years 
with asthma attacks, receiving inhaled β-adrenergic agent 
and systemic corticosteroids were compared. Although 
there were no differences in the clinical score after 2 hours 
of treatment (mean score 6 and 6.5 for salbutamol and 
aminophylline groups, respectively, p  =  0.93), there was 
a tendency toward a longer use of oxygen in the salbuta-
mol group [(17.8 hours (95% CI 8.5 to 37.5) x 7.0 hours 
(95%  CI 3.4 to 14.2)]. We also observed a significantly 
greater increase (p = 0.02) in the time of hospitalization of 
the salbutamol group [(85.4 (95% CI 66.1 to 110.2) hours 
x 57.3 hours (95% CI 45.6 - 72.0)] (A)32.
Aminophylline has a narrow therapeutic safety margin 
and can have toxic and side effects. In comparison with 
the placebo group, in 31 children aged 5 to 18 years treated 
with inhaled β2-adrenergic and systemic corticosteroids, 
the group receiving aminophylline had a higher incidence 
of nausea, vomiting, headache, abdominal pain and palpi-
tations (absolute risk reduction of 37 % – p < 0.05) (A)33.
RECOMMENDATION
Aminophylline is not recommended for the initial treat-
ment of acute asthma. It can be used in severe cases with 
poor response to β2-adrenergic agents and steroids (A)31,32.
12. IS INTRAVENOUS MAGNESIUM SULPHATE EFFECTIVE IN 
THE TREATMENT OF SEVERE ASTHMA ATTACK? IS IT SAFE?
The routine intravenous administration of high doses 
of magnesium sulfate in the beginning of the treatment of 
moderate to severe asthma episodes was not more effec-
tive than the β2-agonists and corticosteroids alone (A)34.
However, in patients older than six years of age, with 
moderate to severe asthma attack that did not respond 
to conventional treatment, there was lung function im-
provement and reduced hospitalization rates in the group 
treated with intravenous magnesium sulfate (A)35.
It was also observed improvement in clinical scores 
and oxygen saturation, reducing the hospitalization time 
in the group treated with intravenous magnesium sul-
fate (A)36.
At the doses used (25 to 75 mg/kg, single dose, infused 
slowly from 20 to 30 minutes), addition of magnesium 
sulfate to conventional treatment of acute asthma attack 
showed no increase in side effects, being safe (A)36,37.
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RECOMMENDATION
Routine addition of intravenous magnesium sulfate at the 
beginning of the treatment of acute asthma attack is inef-
fective (A)34.
Addition of intravenous magnesium sulfate to the con-
ventional treatment of children and adolescents with an 
asthma attack that did not respond to conventional treat-
ment (inhaled β2-agonists and systemic corticosteroids) 
is recommended as it improves lung function, oxygen-
ation and clinical score and reduces the hospitalization 
rate (A)35-37.
Further research involving all degrees of severity of 
asthma attacks and in younger children is necessary. 
13. CAN ANTILEUKOTRIENES BE USED IN THE TREATMENT 
OF ASTHMA ATTACKS?  
There is no evidence to justify the use of antileukotrienes 
as a treatment for asthma attacks. The role of antileukot-
rienes is well-known as prophylactic therapy (A)38. There 
have been few studies that evaluated the efficacy of mon-
telukast in home treatment of asthma attacks in children 
with intermittent asthma. Compared to placebo, the use of 
montelukast for seven days after an acute episode showed 
a modest effect in the prophylaxis of asthma. There was no 
difference regarding the use of health services for asthma 
(OR = 0.65, 95% CI: 0.47 to 0.89), as well as no decrease 
in the need for hospitalization and duration of subsequent 
episodes or use of β2-agonists and corticosteroids. There 
was some symptom and nocturnal awakening reduction 
(14% and ARR was 8.6%, p = 0.043, respectively), as well 
as significant reduction in school and parental work ab-
senteeism (37% and 33%, p < 0.0001 for both) (A)39.
RECOMMENDATION
Antileukotrienes can be used in the treatment of persistent 
asthma, but there is no evidence to justify its use as treat-
ment during an asthma attack (A)38,39.
MAINTENANCE DRUG TREATMENT 
14. ARE INHALED CORTICOSTEROIDS EFFECTIVE AND SAFE 
TO PREVENT ASTHMA ATTACKS IN CHILDHOOD? 
Inhaled corticosteroids are the first choice for the preven-
tion and control treatment of persistent asthma in child-
hood. In mild persistent asthma, treatment with low dos-
es of inhaled corticosteroids (budesonide – 200  mg/d) 
decreased by 14% the need for additional treatment for 
asthma in the first year of treatment compared to placebo. 
Use of budesonide was also associated with a higher in-
crease in FEV1 before and after bronchodilator use, when 
compared with placebo (2.24% and 1.48% of the baseline 
parameters in each group, respectively – p < 0.001) (A)40.
Continuous treatment with corticosteroids is associ-
ated with decreased rates of hospitalization. In a histori-
cal cohort study, including 30,569 patients with asthma, 
the regular use of corticosteroids was associated with a 
31% reduction in the rate of hospitalization for asthma 
(95% CI: 17-43) and 39% in readmissions (95% CI: 25-50). 
Regular use of corticosteroids may prevent approximate-
ly five admissions and 27 readmissions due to asthma in 
1,000 patients per year (A)41.
Prophylactic treatment with inhaled corticosteroids 
is beneficial also in exercise-induced asthma (A)40.
The continuous use of inhaled corticosteroids may 
cause a small reduction in growth rate, especially in the 
first year of use. Compared with placebo, budesonide was 
associated with a reduction of 0.43 cm/year (p = 0.001). 
Inhaled fluticasone was associated with a slight difference 
in height percentile, compared to placebo after two years 
(fluticasone: 51.5% vs. 56.4% placebo, p = 0.001). At the 
end of the treatment period, children who used inhaled 
corticosteroids or placebo had similar growth rates (A)42.
RECOMMENDATION
Use of inhaled corticosteroids is recommended as first 
maintenance therapy choice for children with persistent 
asthma  (A)40,41. This therapy may be associated with 
small delay in the growth rate during treatment, but 
growth velocity is normalized after the end of the treat-
ment (A)42.
15. ARE LONG-ACTING E-AGONISTS (LABA) SAFE FOR 
CHILDREN?
LABA can be beneficial as adjuvant in the treatment of 
moderate to severe persistent asthma or not responsive 
to corticosteroids, as they may effectively promote asth-
ma control with a satisfactory safety level (A)40,43.
In older children and adolescents, these drugs 
should not be used as a single drug, as some studies 
have raised the possibility that they may be associated 
with serious events and asthma-related death. A recent 
systematic review of the literature emphasizes that the 
use of LABA as monotherapy reduces exacerbations 
requiring treatment with corticosteroids, but with sig-
nificant increase in mortality associated with asthma 
(RR: 3.84, 95% CI: 1.21 to 12.14). The subgroup analy-
sis suggests that in children, the use of salmeterol and 
duration of treatment for more than 12 months are as-
sociated with increased risk of serious adverse effects. 
The combination of LABA and IC reduces the risk of 
asthma exacerbations (RR ¼ 0.73, 95% CI, 0.67 to 0.79) 
and hospitalizations (RR ¼ 0.58, 95% CI, 0.45 - 0.74); 
children and the use of salmeterol are also associated 
with increased severe events compared to adults and the 
use of formoterol.
RECOMMENDATION
LABA can be beneficial as adjuvant in the treatment of 
moderate persistent asthma or not responsive to corti-
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costeroids. If used, they should be associated with in-
haled corticosteroids for the shortest time possible, be-
cause the risk of serious adverse events is associated with 
monotherapy, pediatric patients and time of use longer 
than 12 months (A)40,43. 
16. ARE ANTILEUKOTRIENES SUPERIOR TO INHALED CORTI-
COSTEROIDS IN ASTHMA PROPHYLAXIS? 
No. Many studies have shown the effectiveness of antileu-
kotrienes in the treatment of persistent asthma, in addition 
to their beneficial effect in decreasing bronchial hyperre-
activity in asthmatic children (A)38,44,45. However, inhaled 
corticosteroids are more effective in the prophylactic treat-
ment of asthma. In adolescents aged > 15 years, treatment 
with antileukotrienes had lower efficacy when compared to 
inhaled corticosteroids (beclomethasone 200 mg – 2x/day). 
The combination of two drugs in adolescents with asthma 
not controlled with IC was beneficial and improved the 
clinical picture and pulmonary function (FEV1). Also in 
adults with mild to moderate asthma, treatment with IC 
(beclomethasone – 200 mg – 2x/day) has superior efficacy 
to treatment with leukotriene. Further studies are neces-
sary with children (A)46,47.
RECOMMENDATION
Antileukotrienes are effective in controlling persistent 
asthma, but are less effective than inhaled corticosteroids, 
which are the drug of choice in this clinical situation (A)47.
17. IS THE SPECIFIC RECOMBINANT HUMANIZED MONOCLO-
NAL ANTIBODY (ANTI-IGE OMALIZUMABE) EFFECTIVE IN PRE-
VENTING ALL TYPES OF ASTHMA IN CHILDHOOD? CAN IT BE 
USED AT ANY AGE RANGE?  
Omalizumab is recommended for patients with severe 
asthma not controlled by currently available medications 
and mediated by IgE. These patients can be characterized 
by presenting high IgE levels (around 30 mg/dL) and posi-
tive skin and/or specific IgE response to a common aeroal-
lergen. In a systematic review, the use of omalizumab in 
adults and children with severe atopic asthma (IgE be-
tween 30 and 700 mg/dL) allowed the decrease or complete 
withdrawal of treatment with inhaled corticosteroids. The 
number of patients that decreased by up to 50% the use of 
IC was higher in the group receiving omalizumab than in 
the placebo group (OR = 2.50 95% CI 2.02 to 3.10) as well 
as the number of patients that completely stopped the use 
of IC (OR = 2.50, 95% CI 2.00 to 3.13) (A)48.
To date, omalizumab has not been approved for pa-
tients younger than 12 years of age. Further studies are 
needed to evaluate the efficacy and safety in younger chil-
dren. There are some promising trials in this age group. 
A randomized clinical trial included 334 children aged 6 
to 12 years with moderate to severe atopic asthma who 
required inhaled corticosteroids. The proportion of chil-
dren that were able to withdraw the steroid treatment was 
higher in the omalizumab than in the control group (55% 
x 39% - p = 0.004). 
The proportion of children who received omalizumab 
and could reduce the dose of corticosteroids was also high-
er (p = 0.002) and this reduction was greater in the treated 
group (A)49.
RECOMMENDATION
Omalizumab is recommended for patients with severe asth-
ma non-controlled by currently available medications and 
mediated by IgE. It can be administered to children older 
than 12 years (A)48.
18. IS BAMBUTEROL EFFECTIVE AND SAFE FOR THE TREAT-
MENT OF ALL TYPES OF ASTHMA IN CHILDHOOD?
Bambuterol is a β-adrenergic long-acting bronchodilator, 
a prodrug that is slowly metabolized into terbutaline. It 
is available in liquid form for oral use, as a single dose, 
once daily.
There is no evidence in the literature to support the use 
of bambuterol as the drug of choice in the treatment of 
asthma in childhood, as the route of choice for broncho-
dilators is the inhaled one and there are no comparative 
studies in children. A clinical trial in children aged 2 to 12 
years compared bambuterol with daily use of oral terbu-
taline and showed that both showed to be equivalent and 
safe; however, the preferred route for administration of 
β-adrenergic agents (terbutaline) is the inhaled route (B)50.
RECOMMENDATION
Bambuterol, a liquid bronchodilator used by oral route, is 
not recommended as the drug of choice in the treatment 
of asthma (B)50.
19. ARE CHROMONES AS EFFECTIVE AS CORTICOSTEROIDS IN 
THE MAINTENANCE TREATMENT OF ASTHMA IN CHILDHOOD?
No. Comparative studies have shown that inhaled cor-
ticosteroids are more effective in controlling persistent 
asthma. In pre-school children, the mean rate of exacer-
bations per year was 27% higher in children treated with 
cromolyn sodium than in those treated with budesonide 
(p < 0.001) (A)51. In schoolchildren, the use of cromolyn 
was not associated with improvement in FEV1 after four 
months of treatment, whereas in the group receiving 
budesonide and fluticasone, the increase in FEV1 com-
pared to baseline values was 8.2% and 5.4%, respectively 
(p = 0.01 for both) (B)52. Moreover, younger children aged 
less than 36 months, treated with budesonide had lower 
exacerbation rates when compared with those treated with 
cromolyn (5.4% vs. 31.7%, p = 0.003), higher proportion 
of days without coughing (80% x 65 %, p  =  0.014) and 
nights without coughing (89% vs. 78%, p = 0.016) during 
the treatment (A)53.
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RECOMMENDATION
Inhaled corticosteroids are more effective than chromones 
for the control of persistent asthma (A)51,53 (B)52.
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